Össur: Q2 expected to be soft, with tough comps - ABG - Börskollen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Aktieanalys

Össur: Q2 expected to be soft, with tough comps - ABG

{newsItem.title}

Volatile APAC and cost base negatively impacting Q2 We expect FY’22 EBITDA guidance to be under pressure Fair value range down to DKK 26-56 (32-60) Q2 focus likely to be on outlook and LT strategy Going into the Q2 report, we expect a rather soft quarter with an organic group sales growth of ~4% (company collected consensus 3.5%) on the back of a very strong Q2’21 (organic growth of 32%). This is in line with the communication from the company that FY’22 will be back-end loaded. However, we note that consensus estimates from pre-Q1 to pre-Q2 have been downward adjusted (FY’22 revenue estimates down ~3% and net profits down ~11%). We expect these downward adjustments to reflect the ongoing volatility seen in the APAC region, with China still utilising lockdowns, and the continued high cost pressure. Overall, we expect the Q2 numbers to be soft with the focus going into the report likely to be on 1) Industry outlook (M&A activity, shake-up at main competitor Ottobock, which lost both its CEO and CFO in May), 2) cost base management and 3) the long-term strategy, which will likely be evaluated now that the executive team is complete, with the new CFO (Gudny Arna Sveinsdottir) joining on 1 September.

USD 13m in extra costs for FY’22 starting to seem low Looking at the FY’22 guidance, we know that it takes into consideration a negative impact from China in Q2, but it now seems that China will not reopen fully in Q3 either, which would cast a shadow of doubt over the current organic revenue guidance of 6-9% (ABGSCe and cons. both at 6.2%). Additionally, we know that the implemented price increases (~2.5% on a group level, effective mid Q1’22) were to counter the ~USD 13m in extra costs under the current guidance (USD 7m in H1, USD 6m in H2). Based on the continued inflation, however, we expect the EBITDA margin, which is currently guided at 20-21% (ABGSCe 19.6%, cons. 19.9%), to be squeezed.

Q2 is not likely to be a major share price trigger We update our scenario-based estimate ... Läs mer på ABG Sundal Collier

Länk till analysen i sin helhet: https://cr.abgsc.com/foretag/ossur/Equity-research/2022/7/ossur---q2-expected-to-be-soft-with-tough-comps/

Nyheter om Embla Medical

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!

STÄNG X
Populär sparapp – över 500 000 nedladdningar
Många och höga externa omdömen
Högst grad av diversifiering
Perfekt för regelbundet månadssparande
KOM IGÅNG

Nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 får automatiskt 50 procent rabatt på Optis avgift i 3 månader

Om aktien Embla Medical

Senaste nytt